Integrins modulate signaling by growth factor receptors, but their role during tumorigenesis is not clear. Guo et al. (2006) now demonstrate that α6β4 integrin cooperates with ErbB2 in the formation of mammary tumors and discover distinct pathways that regulate cellular proliferation and adhesion downstream of the ErbB2-integrin complex.
Remodeling of bone involves resorption of bone by osteoclasts followed by the differentiation and activity of osteoblasts, the cells that build bone (Hattner and Frost, 1962) . The molecular mechanisms responsible for the cellular communication between osteoclasts and osteoblasts that control bone homeostasis remain one of the central issues in bone cell biology. A recent paper in Cell Metabolism by Zhao et al. (2006) now suggests that ephrin signaling is critical to the two-way communication between osteoclasts and osteoblasts.
Resorption of bone by osteoclasts is stimulated by systemic hormones including parathyroid hormone and cytokines, such as interleukin-1. These hormones stimulate osteoclast formation and activation indirectly by stimulating osteoblasts to produce soluble and membrane bound proteins, such as RANKL (receptor activator of NF-κB ligand) and macrophage colony-stimulating factor (M-CSF). The intracellular signaling molecules responsible for mediating the effects of these two critical factors have been well characterized over the past decade (Teitelbaum and Ross, 2003) .
However, the other aspect of bone remodeling that has baffled investigators is the complex signaling that regulates osteoblast chemotaxis, proliferation, differentiation, and function following resorption by osteoclasts. Bone resorption ceases in sites of bone remodeling, and osteoblasts are attracted to the bone "defects" induced by resorption and then remodel and reform the bone to repair them. This coupling of osteoclastic bone resorption and osteoblastic bone formation is of great importance because all of the known diseases of bone that result in changes in bone mass are due to specific aberrations of this cooperative process. Thus, bone diseases and the drugs used to treat them involve or target elements of osteoclast/osteoblast coupling.
A number of mechanisms have been proposed to explain osteoclast/osteoblast coupling. One theory, now discounted, is that osteoclasts and osteoblasts are in the same lineage, that is, osteoblasts are derived from osteoclasts (Rasmussen et al., 1974) . Others have proposed that growth factors, such as Insulin-like Growth Factor-1 and Transforming Growth Factor β, that are released from the bone matrix as a consequence of resorption are responsible for the events involved in bone formation by osteoblasts (Hayden et al., 1995) . This concept has not yet been disproved, although the growth factors implicated have effects above and beyond those necessary to mediate coupling. A third theory is that osteoclasts, as they cease resorption, release factors that are responsible for subsequent cellular events (Parfitt et al., 1996) . The notion of osteoclast-to-osteoblast coupling is supported by studies with genetically engineered animals such as mice with a disrupted SHPras-MAPK pathway and mice lacking osteoprotegerin (OPG), a secreted protein related to the tumor necrosis factor receptor family. These mice exhibit enhanced bone formation following an increase in osteoclast activity. Based on these observations, it has recently been proposed that the initiation of bone formation requires osteoclasts to be transiently activated to enable them to produce the coupling activity (Martin and Sims, 2005) .
However, an entirely different explanation for the coupling between osteoclasts and osteoblasts during bone remodeling is now presented by Zhao and colleagues (2006) . The authors use mouse models to demonstrate forward and reverse (better termed bidirectional) signaling between osteoclasts and osteoblasts. This bidirectional signaling is mediated by the transmembrane ephrinB2 ligand in osteoclasts and EphB4, a tyrosine kinase receptor, in osteoblasts. Their results suggest that these molecules may account for some of the critical, albeit unexplained, events during normal bone remodeling, namely the cessation of osteoclast activity mediated by osteoblasts and the coupling of new osteoblastic bone formation to the resorption of bone by osteoclasts.
There are two classes of ephrins, the B class (ephrin B1 to B3) are ligands for EphB tyrosine kinase receptors (B1 to B6), whereas class A ephrins (A1 to A5) are ligands for The activities of osteoclasts, which degrade bone, and osteoblasts, which form bone, are coordinated to maintain bone homeostasis. Zhao et al. (2006) now demonstrate bidirectional signaling between these two cell populations via the transmembrane ligand ephrinB2 expressed by osteoclasts and its receptor EphB4 expressed by osteoblasts. Such bidirectional signaling limits osteoclast activity while stimulating osteoblast differentiation.
Boning up on Ephrin Signaling
GPI-anchored EphA receptors (A1 to A10). Ephrins have the capacity for bidirectional signaling. That is, when a cell expressing an ephrin receptor contacts a cell expressing an ephrin ligand, signals are transduced into both the ephrin receptorexpressing cell (forward signaling) and the ephrin ligand-expressing cell (reverse signaling). This type of signaling induces various cytoskeletal responses including remodeling of F actin fibers and focal adhesions in axonal pathfinding. Additional functions for ephrin and ephrin receptors in other cell types include the regulation of tissue morphogenesis, neuronal plasticity, immune response, and angiogenesis (Wilkinson, 2000) . In bone biology, ephrinB and EphB receptors control patterning of the developing skeleton (Compagni et al., 2003) , and disruption of ephrin signaling is implicated in a syndrome called craniofrontonasal syndrome (CFNS [MIM 304110]) (Wieland et al., 2004) . Patients affected by this disease display skeletal abnormalities including craniofacial, thoracic, and limb defects. Similarly, mice lacking ephrinB1 display defects of the axial and appendicular skeleton, such as the asymmetric attachment of ribs, the absence of joints, and polydactyly (Twigg et al., 2004) .
The study of Zhao et al. focuses on ephrinB2 and EphB4 and their effects on bone remodeling in adult mice. EphrinB2 and ephrinB1 are expressed by osteoclasts in the absence of any detectable Eph receptor, whereas osteoblasts express both ephrins and Eph receptors. Using osteoblast-osteoclast coculture assays, as well as loss-and gain-of-function studies in vitro, the authors demonstrated that reverse signaling from EphB4 in osteoblasts to ephrinB2 in osteoclast progenitors leads to the inhibition of osteoclast differentiation. Manipulation of the cytoplasmic region of ephrinB2 allowed the authors to demonstrate that this inhibitory signal is mediated via interaction with PDZ domain proteins but not by tyrosine phosphorylation, thus raising the possibility that PDZ domain proteins may be useful drug targets. Moreover, molecular analyses revealed that ephrinB2 reverse signaling in osteoclasts requires inhibition of Fos and NFATc1 transcription. The authors surprisingly found that mice lacking ephrinB2 specifically in osteoclasts did not have a significant bone phenotype, likely due to the redundancy of ephrinB1 and ephrinB2.
In the second part of the study, Zhao et al. demonstrated that forward signaling between the extracellular domains of ephrinB2 and EphB4 in osteoblasts stimulates their differentiation, a process that may be dependent on RhoA inactivation in osteoblasts. In addition, forced expression of EphB4 in osteoblasts in vivo increased bone mass by enhancing bone formation and decreasing bone resorption. These results confirm that EphB4 has a positive effect on osteoblast differentiation and indicate that osteoclast differentiation and function are suppressed in these transgenic mice. Moreover, they show that this phenotype is independent of any effect on RANKL, CSF-1, or OPG. Thus, in the scenario presented by Zhao et al., reverse signaling from osteoblasts to osteoclasts attenuates osteoclast differentiation, and forward signaling from osteoclasts to osteoblasts favors bone formation at sites where bone resorption had recently occurred (Figure 1) .
It is interesting that in the study by Zhao et al., mice that conditionally lack ephrinB2 do not have a bone phenotype, which suggests a potential role of ephrinB1 in bone biology. Yet, as EphB4 binds only to ephrinB2, if ephrinB1 has a role in bone remodeling it must involve binding to an EphB receptor in osteoblasts other than EphB4. Moreover, the involvement of RhoA in EphB4 forward signaling will need to be confirmed. For example, expressing active RhoA in osteoblasts may block the ability of ephrinB to promote osteoblast differentiation. EphB4 and ephrinB2 downstream signaling pathways will also need to be defined to identify potential new therapeutic agents aimed at uncoupling bone formation and resorption and thus achieve an anabolic response that could complement the anticatabolic drugs available today.
This study raises a number of other additional general questions that will be important to understanding the Osteoclasts are responsible for the resorption of a localized packet of bone, and when they cease their activity, a team of osteoblasts is attracted to the resorption site, where they proliferate, differentiate, and then reform the packet of bone. (Inset) Ephrin-Eph forward signaling from osteoclasts to osteoblasts may be responsible for driving the formation of the new bone packet, and ephrin-Eph reverse signaling may be responsible for the cessation of continued bone resorption by osteoclasts. Integrins are heterodimeric cell surface receptors used by cells to interact with the extracellular matrix (ECM). In addition to performing a structural role, integrins are major sites of signal initiation and modulation. In particular, integrins and receptor tyrosine kinases (RTKs) form a cooperative signaling network to regulate various biological processes (Hynes, 2002; Miranti and Brugge, 2002) . For instance, integrin adhesion promotes activation of several RTKs, including the epidermal growth factor receptor (EGFR). Conversely, RTKs affect cell adhesion, spreading, and migration by regulating integrin localization and activation. Cooperative signaling between RTKs and integrins may also have a role in cancer. Even though aberrant activation of RTKs and changes in integrin expression are involved in epithelial malignancies (carcinoma), it remains unclear how cooperation between integrins and RTKs regulates the initiation of tumor formation and progression to carcinoma.
In this issue of Cell, Guo et al. (2006) establish that α6β4 integrin, which binds to laminin in the ECM, is required for mammary tumorigenesis induced by expression of ErbB2, a member of the EGFR family of RTKs. ErbB2 is a dominant oncogene in breast cancer, and it is amplified in 25%-30% of human breast cancers. Amplification of ErbB2 correlates with poor clinical prognosis in patients whose cancer has progressed to the lymph nodes. ErbB2 is also the target of the drug Herceptin (Citri and Yarden, 2006) . Guo and colleagues exploited two mouse models, one that has a targeted deletion of the
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